Yasuhisa Fujii
Prof Yasuhisa Fujii is an expert in Urology at Tokyo Medical and Dental University (Japan). As of November 2026, ScienceLeadR ranks Yasuhisa Fujii in the top 1% of experts worldwide for Urologic Neoplasms, Kidney Neoplasms and Urinary Bladder Diseases. Yasuhisa Fujii has authored 799 publications, the most recent in 2026, and is an investigator in 7 clinical trials, 2 of them ongoing. SLR score: 3,186 (community average: 125). How the SLR is computed.
LeadR Profile
Urology
Subspecialties: Oncology - Nephrology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2002 - 2026Tokyo Medical and Dental University
2003 - 2026
Tokyo Metropolitan Institute of Medical Science
2024 - 2026
Tokyo University of Science
2025 - 2026
Number : 799
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 7
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK 3475) Versus Neoadjuvant Chemotherapy for Cisplatin Eligible Muscle Invasive Bladder Cancer (MIBC) (MK 3475 B15 KEYNOTE B15 EV 304) NCT04700124 — urinary bladder, urinary bladder neoplasms, cells, b7-h1 antigen, lewy bodies, muscles, lymph nodes, parkinson disease, surgical procedures, operative, neoplasms, duration of therapy, drug therapy, cystectomy, lymph, therapeutics, random allocation, ligands, cell death, dissection, chemotherapy | Phase 3 | Active not recruiting | 2021 |
| A Study of Belzutifan (MK 6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK 6482 011) NCT04586231 — cells, administration, oral, carcinoma, renal cell, therapeutics, carcinoma | Phase 3 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map